---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic impact on families"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Economic impact on families. Topics: Out-of-pocket share of US spending on treatment of hypertension, 2019; Cost-related medication nonadherence among US adults with hypertension: National Health Interview Survey 2017; Cost-related medication nonadherence by age, sex, and insurance status: National Health Interview Survey 2019 to 2022; Additive copays for multiple medications: patient input. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Hypertension on Families

<a id="topic-2.2.1.8.3-1"></a>

### Out-of-pocket share of US spending on treatment of hypertension, 2019

| Payer | Share of 2019 spending on treatment of hypertension, % |
| --- | --- |
| Medicare | “39.9” |
| Medicaid | “14.3” |
| Private insurance | “29.3” |
| Out of pocket | “16.6” |

Source: [Dieleman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11829247/)

<a id="topic-2.2.1.8.3-2"></a>

### Cost-related medication nonadherence among US adults with hypertension: National Health Interview Survey 2017

> “Participants with self-reported hypertension from the 2017 National Health Interview Survey were included (n = 7,498).”
> “Overall, 10.7% reported CRMN, 83.6% reported current antihypertensive medication use, and 67.4% reported normal blood pressure within past 12 months. Adjusted percentages of current antihypertensive medication use (88.6% vs. 82.9%, P < 0.001) and self-reported normal blood pressure (69.8% vs. 59.5%, P = 0.002) were higher among those without CRMN compared with those with CRMN.”
> “Financial barriers to medication adherence persist and impact hypertension management.”

Source: [Fang et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32369108/)

<a id="topic-2.2.1.8.3-3"></a>

### Cost-related medication nonadherence by age, sex, and insurance status: National Health Interview Survey 2019 to 2022

> “This analytical cross-sectional study utilized data from the National Health Interview Survey Sample from 2019 to 2022.”
> “Women aged 18-64 years more likely (adjusted odds ratio (aOR) 1.44; 95% CI 1.18, 1.75) to experience CRN than men. Notably, uninsured individuals in both the 18-64 (aOR 2.21; 95% CI 1.51, 3.25) and ≥ 65 (aOR 5.55; 95% CI 1.36, 22.75) age groups were at increased risk of facing CRN.”
> “To mitigate CRN, health quality strategies like prescribing generics, connecting patients with assistance programs, and implementing policies to reduce out-of-pocket costs are essential.”

Source: [Reddy et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40285540/)

<a id="topic-2.2.1.8.3-4"></a>

### Additive copays for multiple medications: patient input

> “Clinical inertia, pill burden, additive copays for multiple medications, variable tolerance for side effects, and a lack of awareness of the importance of treating hypertension can make treatment challenging.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.1.8.3-5"></a>

### Caregiver time and cost burden in uncontrolled or resistant hypertension

No evidence found.

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
